Why Surgical Oncologists Get Sued: Positive Margins, Staging Errors, and Delayed Operative Intervention

By John Mahoney · July 2026 · 8 min read

Surgical oncology sits at a dangerous intersection: the patient already has cancer, the stakes are life-and-death, and the surgeon's decisions — when to operate, how much to resect, whether the margins are clear — directly determine whether the disease is cured or returns. When a cancer recurs after surgery, the question a plaintiff attorney has to answer is whether the recurrence reflects the biology of an aggressive tumor or a surgical failure that left disease behind. That distinction is the whole case.

This guide is for plaintiff-side medical-malpractice attorneys evaluating cancer-surgery matters. It covers the allegation profile, the cannot-miss scenarios, the contributing factors that drive payouts, and what separates a strong surgical-oncology case from a weak one — with the caution that these cases live or die on causation and on distinguishing the surgeon's role from that of the pathologist, oncologist, and radiologist who share the patient.

Disclaimer: This article is for informational purposes only and does not constitute legal advice. The patterns here are directional and drawn from general surgical and oncology closed-claim analogues; they should be independently verified against the record before use in any matter.

The Allegation Profile

Cancer-surgery claims cluster into recognizable categories, spanning both the operation itself and the judgment around it:

• Positive or inadequate surgical margins. The dominant technical allegation — tumor left at the resection edge, an inadequate margin that guidelines would call insufficient, and a failure to re-excise when the pathology came back positive.
• Staging and nodal-assessment errors — inadequate lymph-node sampling, a missed or mis-sampled sentinel node, incomplete staging that led to under-treatment.
• Delayed operative intervention — a resectable cancer where surgery was deferred past the window in which it was curable, or a failure to escalate to definitive surgery.
• Wrong-site, wrong-specimen, and specimen-handling errors — operating on the wrong side or lesion, mislabeled or lost specimens that corrupted the pathology, retained surgical items.
• Missed synchronous or additional lesions — a second primary or an additional focus on preoperative imaging that was not addressed at operation.
• Informed-consent failures — inadequate disclosure of recurrence risk, alternatives, or the possibility of positive margins requiring further surgery.
• Postoperative and complication management — failure to recognize and treat a leak, bleed, or infection that turned a routine complication into a catastrophe.

The Cannot-Miss Scenarios

A handful of fact patterns recur and should elevate merit and exposure on intake:

• The positive margin that was never re-excised. Final pathology reports tumor at the margin, the standard called for re-excision or additional treatment, and nothing happened — the result returned and the loop never closed. When the cancer recurs locally, this is often the strongest surgical-oncology pattern because the standard is concrete and the closed-loop failure is documented on the pathology report.
• The abnormal pathology or imaging that sat. A staging scan or a pathology finding that returned and was not acted on — no re-operation, no referral to adjuvant therapy, no change in plan.
• The delayed resection. A resectable tumor where definitive surgery was deferred, and the tumor progressed to unresectable or metastatic disease in the interval.
• The wrong specimen or wrong site. A mislabeled specimen, a biopsy of the wrong lesion, or surgery on the wrong side — errors that are hard to defend and that corrupt every downstream decision.
• The missed second lesion. An additional focus visible on preoperative imaging that was never addressed, surfacing later as a recurrence.

The single highest-value pattern is the positive margin that returned on final pathology and was never re-excised, followed by a local recurrence. It combines a concrete standard, a documented closed-loop failure, and a causation story — timely re-excision would have changed the outcome — that survives scrutiny.

The Contributing Factors That Drive Payouts

Cancer recurs even after flawless surgery, so what converts a recurrence into a payable claim is usually one of these:

• Failure to act on the pathology report. In surgical oncology the pathology report is the critical result, and the defining systemic failure is the positive margin, the understaged specimen, or the inadequate nodal sampling that returned and did not change the plan.
• Communication failures across the tumor board. Cancer care is multidisciplinary — surgeon, pathologist, radiologist, medical and radiation oncology. The recurring fault line is the handoff: the pathology result that never reached the surgeon, the tumor-board recommendation that was never executed, the referral to adjuvant therapy that never happened.
• Clinical-judgment and technical failures. An inadequate resection, insufficient margins, incomplete staging — and the judgment call to defer surgery that should have proceeded.
• Documentation and consent gaps. Absent evidence that positive margins were disclosed and a re-excision offered, missing operative detail on the extent of resection.

The defining surgical-oncology question is whether the pathology result was acted on and whether the resection met the standard. A documented re-excision after a positive margin — or a defensible margin with clean pathology — is a strong defense; a positive margin that returned and sat while the cancer recurred is the plaintiff's case.

What Separates a Strong Case From a Weak One

The strong plaintiff case

• A documented positive or inadequate margin (or an understaged specimen) that the standard required be addressed, where the surgeon owned the decision and the loop was never closed.
• A local recurrence that followed the unaddressed margin, with a clean causation story that timely re-excision or complete staging would have changed the outcome.
• A wrong-site or wrong-specimen error — strong on liability — paired with a showing that the error actually harmed the patient.

The strong defense case

• A margin-negative resection with complete staging, documented and executed — the recurrence is the disease, not the surgery.
• The attribution defense: the failure belonged to the pathologist who mis-read the specimen, the oncologist who withheld adjuvant therapy, or the radiologist who missed the second lesion — not the surgeon.
• Causation: an aggressive tumor biology, not the operative decision, drove the outcome — a frequent and strong defense given how gravely ill these patients are.

The weak case treats any recurrence as automatic negligence and ignores tumor biology. Recurrence after a margin-negative resection is often the disease, not the surgery. A plaintiff theory has to fix attribution across the multidisciplinary team and defeat the biology defense with the record — the pathology reports, the operative notes on the extent of resection, the staging studies, and the tumor-board documentation — not with specialty-wide statistics.

Bottom Line

Surgical oncology is high-severity, and its defining claim is the positive margin that returned on pathology and was never re-excised — followed by staging and nodal errors, delayed resection, and wrong-specimen mistakes. These cases turn on whether the pathology result was acted on, whether the resection met the standard, whether the surgeon actually owned the decision, and whether the recurrence reflects the surgery or the tumor's biology. Screen for the closed-loop failure on the pathology report, fix attribution across the multidisciplinary team, pressure-test causation against tumor biology early, and build the timeline from the record itself.

For how damages exposure varies across jurisdictions, see our medical malpractice damages-by-state tool, and if a pre-suit expert filing is required, run the certificate of merit readiness checker before drafting.

Questions? Contact us at [email protected] or (856) 979-6525

🔎 Screening a case in a different specialty? Browse all specialty malpractice-risk guides in one place — Why Doctors Get Sued: Malpractice Risk by Specialty →